BACKGROUND: There is presently no effective therapy for relapsing, metastatic, androgen-independent prostate cancer. Immunotherapy with monoclonal antibody-vehicled toxins (Immunotoxins, ITs) may be a promising novel treatment option for the management of prostate cancer in these cases. METHODS: Three anti-prostate specific membrane antigen (anti-PSMA) monoclonals (J591, PEQ226.5, and PM2P079.1) were cross-linked to ricin A-chain (RTA; native or recombinant), and their cytotoxic effects were investigated in monolayer and three-dimensional (3-D) cell cultures of prostate carcinoma cells (LNCaP). RESULTS: The various Immunotoxins showed effects in the nanomolar range (IC(50s) of 1.6-99 ng/ml) against PSMA+ cells (IC(50) being the concentration inhibiting 50% cell proliferation or protein synthesis). PSMA(-) cell lines were 62- to 277-fold less sensitive to anti-PSMA ITs, evidencing an appreciable therapeutic window. Treatment with J591-smpt-nRTA (0.35-31.7ng/ml) resulted in complete eradication of 3-D tumor micromasses or in 1.46- to 0.35-log reduction of target cells number, depending on the dose. CONCLUSION: Anti-PSMA ITs appear to be promising for use in the eradication of small prostate tumor cell aggregates present in tissues and in the bone marrow. Copyright 2002 Wiley-Liss, Inc.
BACKGROUND: There is presently no effective therapy for relapsing, metastatic, androgen-independent prostate cancer. Immunotherapy with monoclonal antibody-vehicled toxins (Immunotoxins, ITs) may be a promising novel treatment option for the management of prostate cancer in these cases. METHODS: Three anti-prostate specific membrane antigen (anti-PSMA) monoclonals (J591, PEQ226.5, and PM2P079.1) were cross-linked to ricin A-chain (RTA; native or recombinant), and their cytotoxic effects were investigated in monolayer and three-dimensional (3-D) cell cultures of prostate carcinoma cells (LNCaP). RESULTS: The various Immunotoxins showed effects in the nanomolar range (IC(50s) of 1.6-99 ng/ml) against PSMA+ cells (IC(50) being the concentration inhibiting 50% cell proliferation or protein synthesis). PSMA(-) cell lines were 62- to 277-fold less sensitive to anti-PSMA ITs, evidencing an appreciable therapeutic window. Treatment with J591-smpt-nRTA (0.35-31.7ng/ml) resulted in complete eradication of 3-D tumor micromasses or in 1.46- to 0.35-log reduction of target cells number, depending on the dose. CONCLUSION: Anti-PSMA ITs appear to be promising for use in the eradication of small prostate tumor cell aggregates present in tissues and in the bone marrow. Copyright 2002 Wiley-Liss, Inc.
Authors: Tanushree Ganguly; Shorouk Dannoon; Mark R Hopkins; Stephanie Murphy; Hendry Cahaya; Joseph E Blecha; Salma Jivan; Christopher R Drake; Cyril Barinka; Ella F Jones; Henry F VanBrocklin; Clifford E Berkman Journal: Nucl Med Biol Date: 2015-06-09 Impact factor: 2.408
Authors: Marc O Anderson; Lisa Y Wu; Nicholas M Santiago; Jamie M Moser; Jennifer A Rowley; Erin S D Bolstad; Clifford E Berkman Journal: Bioorg Med Chem Date: 2007-08-11 Impact factor: 3.641
Authors: Lisa Y Wu; Jacinda C Do; Marat Kazak; Helen Page; Yoko Toriyabe; Marc O Anderson; Clifford E Berkman Journal: Bioorg Med Chem Lett Date: 2007-10-30 Impact factor: 2.823
Authors: Jessie R Nedrow-Byers; Adam L Moore; Tanushree Ganguly; Mark R Hopkins; Melody D Fulton; Paul D Benny; Clifford E Berkman Journal: Prostate Date: 2012-08-21 Impact factor: 4.104
Authors: Shorouk Dannoon; Tanushree Ganguly; Hendry Cahaya; Jonathan J Geruntho; Matthew S Galliher; Sophia K Beyer; Cindy J Choy; Mark R Hopkins; Melanie Regan; Joseph E Blecha; Lubica Skultetyova; Christopher R Drake; Salma Jivan; Cyril Barinka; Ella F Jones; Clifford E Berkman; Henry F VanBrocklin Journal: J Med Chem Date: 2016-06-13 Impact factor: 7.446
Authors: Lisa Y Wu; Marc O Anderson; Yoko Toriyabe; Jack Maung; Tammy Y Campbell; Cheryl Tajon; Marat Kazak; Jamie Moser; Clifford E Berkman Journal: Bioorg Med Chem Date: 2007-08-21 Impact factor: 3.641
Authors: Fayun Zhang; Liang Shan; Yuanyi Liu; David Neville; Jung-Hee Woo; Yue Chen; Alexandru Korotcov; Stephen Lin; Sophia Huang; Rajagopalan Sridhar; Wei Liang; Paul C Wang Journal: Adv Healthc Mater Date: 2012-11-22 Impact factor: 9.933